<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912024</url>
  </required_header>
  <id_info>
    <org_study_id>2020-04</org_study_id>
    <nct_id>NCT04912024</nct_id>
  </id_info>
  <brief_title>Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study</brief_title>
  <acronym>COMPARE</acronym>
  <official_title>Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study (COMPARE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Outset Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Outset Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System&#xD;
      in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BUN Lab Value</measure>
    <time_frame>Change from baseline BUN measurement at 24 hours.</time_frame>
    <description>Change in Blood Urea Nitrogen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C02 Lab Value</measure>
    <time_frame>Change from baseline CO2 measurement at 24 hours.</time_frame>
    <description>Change in Carbon Dioxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>K Lab Value</measure>
    <time_frame>Change from baseline K measurement at 24 hours</time_frame>
    <description>Change in Potassium</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Tablo Hemodialysis System</arm_group_label>
    <description>Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Hemodialysis System</arm_group_label>
    <description>Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System</intervention_name>
    <description>Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD</description>
    <arm_group_label>Tablo Hemodialysis System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems</intervention_name>
    <description>Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD</description>
    <arm_group_label>Conventional Hemodialysis System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with AKI or ESKD who were prescribed acute intermittent Renal Replacement&#xD;
        Therapy (RRT).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is 18 years of age.&#xD;
&#xD;
          -  Participant weighs ≥ 34kg.&#xD;
&#xD;
          -  Participant was hospitalized and had dialysis dependent End-Stage Renal Disease or&#xD;
             Acute Kidney Injury and was prescribed acute intermittent renal replacement therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatments isolated to ultrafiltration only.&#xD;
&#xD;
          -  Any documented condition the Physician feels would prevent the participant from&#xD;
             successful inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Josh Schumacher</last_name>
    <phone>(669) 231-8200</phone>
    <email>ClinicalTeam@outsetmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adventist Health System</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Allen</last_name>
    </contact>
    <investigator>
      <last_name>Amay Parikh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Health Harris Methodist Hospital Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Drake</last_name>
    </contact>
    <investigator>
      <last_name>Kirsten Drake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tablo</keyword>
  <keyword>Outset Medical</keyword>
  <keyword>ESRD</keyword>
  <keyword>AKI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregate data will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

